← brief for 2026-09-03 · Slowing decline

SGLT2 inhibitors in chronic kidney disease: cardiorenal outcomes, safety, and implementation in primary care

Key takeaways

This is a review article about SGLT2 inhibitors, a class of pills first made for diabetes that also protect the kidneys and heart. It pulls together what earlier trials found and gives advice on prescribing them in regular family practice, including who to start and what side effects to watch for. It is a summary of existing work and reports no new results of its own.

Who did this work

Shamsun Nahar (Augusta University Health) · Sharar Naiarin Haque (Kennesaw State University) · Sananda Halder (Dhaka Medical College and Hospital)

Source

Paper · OpenAlex, CKD works · 2026-09-02
https://doi.org/10.37349/ec.2026.1012120